JP3501237B2 - Mineral absorption enhancer - Google Patents
Mineral absorption enhancerInfo
- Publication number
- JP3501237B2 JP3501237B2 JP08557794A JP8557794A JP3501237B2 JP 3501237 B2 JP3501237 B2 JP 3501237B2 JP 08557794 A JP08557794 A JP 08557794A JP 8557794 A JP8557794 A JP 8557794A JP 3501237 B2 JP3501237 B2 JP 3501237B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- lactobionic acid
- iron
- mineral
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims description 24
- 239000011707 mineral Substances 0.000 title claims description 24
- 238000010521 absorption reaction Methods 0.000 title description 17
- 239000003623 enhancer Substances 0.000 title description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 23
- 229940099563 lactobionic acid Drugs 0.000 claims description 23
- 229940124532 absorption promoter Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 229910052742 iron Inorganic materials 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229950006191 gluconic acid Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 101100513612 Microdochium nivale MnCO gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940036630 folic acid 0.2 mg Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- -1 sucrose fatty acid ester Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
【0001】
【産業上の利用分野】本発明は、ガラクトースとグルコ
ン酸が結合したラクトビオン酸を有効成分とするミネラ
ル吸収促進剤に関する。
【0002】
【従来の技術】日本人のカルシウム摂取量は、長年にわ
たり栄養必要量を下回っている現状にあり、カルシウム
の摂取が求められている。しかしながら、日本人の平均
的な食習慣では十分な量のカルシウムを含む献立を継続
して摂取するのに相当の努力を要する。また、カルシウ
ム以外に亜鉛、銅、マグネシウムなどのミネラルについ
ても不足しがちであり、ミネラルの吸収性が高い食品と
共に、ミネラルの吸収を促進する物質に対しても関心が
高まっている。さらには、出血や鉄欠乏による貧血の治
療や改善には、クエン酸鉄、ピロリン酸鉄、塩化鉄、硫
酸鉄などの鉄剤やビタミンB12製剤などが用いられてい
るが、これらの鉄剤は体内での吸収率が非常に低いため
比較的多量に投与しなければならない。しかし、これら
の製剤を経口投与の場合、多量に投与すると鉄剤は消化
管壁の鉄症や様々な副作用(吐気、むかつき、便秘な
ど)を引き起こすという問題があった。
【0003】一方、既知の物質としてO−β−D−ガラ
クトピラノシル−(1−4)−D−グルコン酸の一般式
で表される二糖類のラクトビオン酸が知られているが、
このラクトビオン酸がカルシウムの吸収を促進するとい
うことは知られていない。
【0004】
【発明が解決しようとしている課題】本発明者らは、上
述したようにカルシウムの吸収を促進する物質を求めて
鋭意研究を重ねた結果、一般式がO−β−D−ガラクト
ピラノシル−(1−4)−D−グルコン酸で表されるラ
クトビオン酸がカルシウムの吸収を促進することを見出
し、本発明を完成するに至った。したがって、本発明
は、ラクトビオン酸を有効成分とするミネラル吸収促進
剤を提供することを課題とする。
【0005】
【課題を解決するための手段】本発明では、一般式がO
−β−D−ガラクトピラノシル−(1−4)−D−グル
コン酸で表されるラクトビオン酸をミネラル吸収促進剤
の有効成分として用いる。このラクトビオン酸は、乳糖
を基質としてラクトースデヒドロゲナーゼ活性を有する
シュードモナス・グラヴェオレンスなどの微生物を作用
させることにより得ることができ、また、乳糖を臭素な
どで酸化することにより得ることもできる。
【0006】このミネラル吸収促進効果を有するラクト
ビオン酸は、ヒトや家畜の生体内で効果を発揮させるた
めに、例えば、糖衣錠やタブレットなどの錠剤、顆粒
剤、液剤、もしくはカプセルなどとして経口的に投与で
きる医薬として、また、飲料、スープ、チーズ、ゼリ
ー、パン、麺類、ソーセージなど、あるいはガムやキャ
ンディーなどの菓子類に添加することにより、ミネラル
吸収促進食品素材として用いることもできる。さらに
は、飼料添加物として用いることもできる。なお、ラク
トビオン酸の摂取量については、特に制約はないが、成
人男子の場合、1mg/kg体重/日以上、望ましくは1〜
1,000mg /kg体重/日が適当である。
【0007】本発明のラクトビオン酸を有効成分とする
ミネラル吸収促進剤は、カルシウム、鉄、マグネシウ
ム、亜鉛、銅などの生体に必要なミネラルの吸収を促進
するので、食事性因子によるミネラルの摂取を改善する
と共に、骨粗鬆症や鉄欠乏性貧血などの症状を改善する
効果も期待される。次に実施例及び試験例を挙げて本発
明を具体的に説明する。
【0008】
【実施例1】常法に従い、表1の配合比によって、ミネ
ラル吸収促進効果を賦与した果汁飲料を製造した。
【0009】
【表1】
(単位:重量%)
────────────────────────────────────
混合異性化糖 15.0
果汁 10.0
クエン酸 1.0
ラクトビオン酸(和光純薬社製) 0.1
香料 0.1
水 73.8
────────────────────────────────────
【0010】
【実施例2】常法に従い、表2の配合比によって、ミネ
ラル吸収促進効果を賦与したゼリーを製造した。
【0011】
【表2】
(単位:重量%)
────────────────────────────────────
果汁 20.0
グラニュー糖 15.0
水飴 5.0
寒天 1.0
ラクトビオン酸(和光純薬社製) 0.5
香料 0.1
水 58.4
────────────────────────────────────
【0012】
【実施例3】本発明のラクトビオン酸を配合したカルシ
ウム吸収促進剤を調製した。カルシウム2,200g、コーン
スターチ1,232g、結晶セルロース100g、カルボキシメチ
ルセルロースカルシウム 68g及びラクトビオン酸 (和光
純薬社製) 400gをニーダーで混合した後、水 500mlを噴
霧滴下しながら混練した。次に、この混練物を20メッシ
ュのスクリーンをセットした単軸オシレーターで造粒
し、流動槽型乾燥機で乾燥した。そして、この乾燥品を
フラッシュミルで粉砕し、整粒して打錠用粉体を得た。
この打錠用粉体に滑沢剤としてショ糖脂肪酸エステル 8
0gをV型混合機で混合した後、直径11mmの杵をセットし
た錠剤機で打錠し、平均重量 0.35gのタブレットを得
た。
【0013】
【実施例4】常法に従い、表3の配合比によって、ミネ
ラル吸収促進効果を賦与した犬飼育用飼料(ドッグフー
ド)を製造した。
【0014】
【表3】
(単位:重量%)
────────────────────────────────────
大豆粕 13.7
脱脂粉乳 14.0
大豆油 4.0
コーン油 2.0
パーム油 2.0
トウモロコシ澱粉 23.0
小麦粉 15.0
ふすま 8.0
ビタミン混合物 2.0
ミネラル混合物 9.0
セルロース 2.3
ラクトビオン酸(和光純薬社製) 0.5
────────────────────────────────────
なお、ビタミン混合物の組成を表4に、ミネラル混合物
の組成を表5にそれぞれ示す。
【0015】
【表4】
────────────────────────────────────
ビタミンA 1,500 IU
ビタミンD3 300 IU
ビタミンE 6.8 mg
ビタミンB1 0.9 mg
ビタミンB2 0.4 mg
ビタミンB6 0.5 mg
ビタミンB12 3.4 mg
ビタミンC 50.0 mg
パントテン酸 4.0 mg
葉酸 0.2 mg
コリン 200.0 mg
ビオチン 24.4 μg
イノシトール 50.0 mg
ナイアシン 10.5 mg
────────────────────────────────────
ショ糖を加えて全量を2gとした。
【0016】
【表5】
────────────────────────────────────
CaCO3 3.0 g
KH2 PO4 2.0 g
NaH2 PO4 1.5 g
MgO 0.5 g
MnCO3 40.0 mg
FeC6 H5 O7 30.0 mg
70%ZnO 10.0 mg
55%CaCO3 4.5 mg
KlO3 0.65 mg
Na2 SeO3 ・5H2 O 0.05 mg
CrK(SO4 )・12H2 O 5.0 mg
────────────────────────────────────
ショ糖を加えて全量を9gとした。
【0017】
【試験例1】ラクトビオン酸のミネラル吸収促進効果に
ついて動物実験を行った。動物実験には8週齢のSD系雄
ラットを用い、1群6匹で行なった。実験食は、表6に
示したように各糖質を5重量%配合したものを用いた。
【0018】
【表6】
(単位:g/100g)
────────────────────────────────────
A群 B群 C群
────────────────────────────────────
カゼイン 20.0 20.0 20.0
コーンスターチ 65.2 60.2 60.2
セルロース 5.0 5.0 5.0
コーンオイル 5.0 5.0 5.0
ビタミンミックス 1.0 1.0 1.0
メチオニン 3.5 3.5 3.5
DL−メチオニン 0.3 0.3 0.3
ラクトース − 5.0 −
ラクトビオン酸 − − 5.0
────────────────────────────────────
A群:対照群、B群:ラクトース投与群、C群:ラクト
ビオン酸投与群
また、各実験食の成分値を表7及び表8に示した。
【0019】
【表7】
(単位:g/100g)
────────────────────────────────────
A群 B群 C群
────────────────────────────────────
糖質 63.19 64.19 64.09
蛋白 17.45 17.39 17.31
脂肪 5.45 5.58 5.45
水分 10.82 9.81 10.10
灰分 3.09 3.03 3.05
────────────────────────────────────
A群:対照群、B群:ラクトース投与群、C群:ラクト
ビオン酸投与群
【0020】
【表8】
(単位:mg/100g)
────────────────────────────────────
A群 B群 C群
────────────────────────────────────
ナトリウム 109 108 97
カリウム 350 350 350
カルシウム 490 490 495
マグネシウム 41 42 42
鉄 3.8 3.9 4.0
亜鉛 3.6 3.7 3.6
銅 0.55 0.55 0.56
マンガン 4.7 5.0 5.0
リン 600 610 610
────────────────────────────────────
A群:対照群、B群:ラクトース投与群、C群:ラクト
ビオン酸投与群
【0021】また、ミネラル吸収率の評価については、
実験食投与1週目に糞便と尿を採取し、排泄されたカル
シウムとマグネシウムを測定して、次式により算出し
た。
ミネラル吸収率(%)=〔(摂取ミネラル量−排泄ミネ
ラル量)/(摂取ミネラル量)×100
【0022】その結果を図1に示す。それによると、ラ
クトビオン酸投与群は、カルシウム吸収物質として知ら
れているラクトース投与群に比べて、カルシウムやマグ
ネシウムなどのミネラル吸収を促進させることが判っ
た。
【0023】
【試験例2】21日齢のウィスター系ラット(体重が45〜
50g)に、鉄含量を0.25mg/100g飼料とした除鉄食(オリ
エンタル酵母社製)を3週間与え、血中ヘモグロビン値
が7g/100ml 以下の貧血ラットを作成した。そして、1
群5匹とし、その後も除鉄食を与え続けながら、下記の
試験飼料を1ml/日、6週間強制経口投与した。
試験群1:除鉄食のみ
試験群2:硫酸第一鉄を鉄として 0.2mg/ml
試験群3:硫酸第一鉄を鉄として 0.2mg/ml+ラクトビ
オン酸を 200mg/ml
試験群4:硫酸第一鉄を鉄として 0.2mg/mlラクトース
を 200mg/ml
試験飼料投与後6週間目に、尾静脈より採血し自動血球
計測装置(東亜医用電子社製)でヘモグロビン値を測定
した。その結果を表9に示した。
【0024】
【表9】
────────────────────────────────────
ヘモグロビン値(平均値±標準偏差)
────────────────────────────────────
試験群1 4.9±0.3 (g/ml)
試験群2 10.5±0.8
試験群3 16.1±1.0
試験群4 11.6±0.9
────────────────────────────────────
【0025】このように、ラクトビオン酸投与群は、無
機鉄である硫酸第一鉄の単独投与群及びラクトース投与
群よりも優れた貧血治療効果を示すことが判った。
【0026】
【発明の効果】本発明のラクトビオン酸は、ミネラルの
吸収性を促進する作用を有するので、このラクトビオン
酸を配合した医薬、飲食品及び飼料は、ミネラルの補給
に有用である。Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a mineral absorption enhancer containing lactobionic acid, in which galactose and gluconic acid are bonded, as an active ingredient. 2. Description of the Related Art Calcium intake of Japanese people has been below nutritional requirements for many years, and calcium intake is required. However, the average dietary habit of the Japanese requires considerable effort to continue to consume menus containing sufficient calcium. In addition, minerals such as zinc, copper, and magnesium other than calcium tend to be deficient, and there is an increasing interest in foods having high mineral absorbency and substances that promote mineral absorption. Furthermore, the treatment and improvement of anemia due to hemorrhage and iron deficiency, iron citrate, iron pyrophosphate, iron chloride, etc. iron and vitamin B 12 preparation, such as iron sulfate are used, these iron is the body Has to be administered in relatively large amounts due to the very low absorption at However, in the case of oral administration of these preparations, when administered in large amounts, iron preparations have the problem of causing ironosis of the digestive tract wall and various side effects (such as nausea, nausea, and constipation). On the other hand, as a known substance, a disaccharide lactobionic acid represented by a general formula of O-β-D-galactopyranosyl- (1-4) -D-gluconic acid is known.
It is not known that lactobionic acid promotes calcium absorption. The inventors of the present invention have conducted intensive studies for a substance that promotes the absorption of calcium as described above, and as a result, the general formula is O-β-D-galactopyra. The inventors have found that lactobionic acid represented by nosyl- (1-4) -D-gluconic acid promotes calcium absorption, and have completed the present invention. Therefore, an object of the present invention is to provide a mineral absorption promoter containing lactobionic acid as an active ingredient. [0005] In the present invention, the general formula is O
Lactobionic acid represented by -β-D-galactopyranosyl- (1-4) -D-gluconic acid is used as an active ingredient of a mineral absorption promoter. This lactobionic acid can be obtained by using lactose as a substrate and allowing microorganisms having lactose dehydrogenase activity such as Pseudomonas graveorens to act thereon, or can be obtained by oxidizing lactose with bromine or the like. [0006] Lactobionic acid having the effect of promoting mineral absorption is orally administered, for example, as tablets, granules, liquids or capsules such as sugar-coated tablets and tablets in order to exert its effect in vivo in humans and livestock. It can also be used as a mineral-enhancing food material by adding it to drinks, soups, cheeses, jellies, breads, noodles, sausages, etc., or confectionery such as gums and candies. Further, it can be used as a feed additive. The amount of lactobionic acid is not particularly limited, but is 1 mg / kg body weight / day or more, and preferably 1 to
1,000 mg / kg body weight / day is appropriate. [0007] The mineral absorption promoter of the present invention containing lactobionic acid as an active ingredient promotes the absorption of minerals necessary for living organisms such as calcium, iron, magnesium, zinc, and copper. It is also expected to have an effect of improving symptoms such as osteoporosis and iron deficiency anemia. Next, the present invention will be specifically described with reference to examples and test examples. Example 1 In accordance with a conventional method, a fruit juice beverage having a mineral absorption promoting effect was produced according to the mixing ratio shown in Table 1. [Table 1] (Unit:% by weight) ──────────────────────────────────── Mixing Isomerized sugar 15.0 fruit juice 10.0 citric acid 1.0 lactobionic acid (manufactured by Wako Pure Chemical Industries) 0.1 flavor 0.1 water 73.8 ─────────────────────────── Example 2 According to a conventional method, a jelly having a mineral absorption promoting effect was produced according to the compounding ratio shown in Table 2. [Table 2] (Unit:% by weight) ──────────────────────────────────── Fruit juice 20.0 Granulated sugar 15.0 Candy starch 5.0 Agar 1.0 Lactobionic acid (manufactured by Wako Pure Chemical Industries) 0.5 Fragrance 0.1 Water 58.4 ──────────────────────────── Example 3 A calcium absorption promoter containing the lactobionic acid of the present invention was prepared. After 2,200 g of calcium, 1,232 g of corn starch, 100 g of crystalline cellulose, 68 g of carboxymethylcellulose calcium and 400 g of lactobionic acid (manufactured by Wako Pure Chemical Industries, Ltd.) were mixed in a kneader, and kneaded while spraying 500 ml of water dropwise. Next, the kneaded material was granulated with a single-screw oscillator equipped with a 20-mesh screen, and dried with a fluidized-bed dryer. The dried product was pulverized with a flash mill and sized to obtain a tableting powder.
The sucrose fatty acid ester 8
After mixing 0 g with a V-type mixer, the mixture was tableted with a tablet machine equipped with a punch having a diameter of 11 mm to obtain a tablet having an average weight of 0.35 g. Example 4 According to a conventional method, a dog breeding feed (dog food) having a mineral absorption promoting effect was produced according to the mixing ratio shown in Table 3. [Table 3] (Unit:% by weight) ──────────────────────────────────── Large Bean meal 13.7 Skim milk powder 14.0 Soybean oil 4.0 Corn oil 2.0 Palm oil 2.0 Corn starch 23.0 Flour 15.0 Bran 8.0 Vitamin mixture 2.0 Mineral mixture 9.0 Cellulose 2.3 Lactobionic acid (manufactured by Wako Pure Chemical Industries) 0.5 0.5 ───────────────────────── The composition of the vitamin mixture is shown in Table 4, and the composition of the mineral mixture is shown in Table 5. [Table 4] ──────────────────────────────────── Vitamin A 1,500 IU Vitamin D 3 300 IU Vitamin E 6.8 mg Vitamin B 1 0.9 mg Vitamin B 2 0.4 mg Vitamin B 6 0.5 mg Vitamin B 12 3.4 mg Vitamin C 50.0 mg Pantothenic acid 4.0 mg Folic acid 0.2 mg Choline 200.0 mg Biotin 24.4 μg Inositol 50.0 mg Niacin 10.5 mg ─ ─────────────────────────────────── Sucrose was added to make the total amount 2 g. [Table 5] CaCO 3 3.0 g KH 2 PO 4 2.0 g NaH 2 PO 4 1.5 g MgO 0.5 g MnCO 3 40.0 mg FeC 6 H 5 O 7 30.0 mg 70% ZnO 10.0 mg 55% CaCO 3 4.5 mg KlO 3 0.65 mg Na 2 SeO 3 · 5H 2 O 0.05 mg CrK (SO 4 ) ・ 12H 2 O 5.0 mg 加 え Add sucrose The total amount was 9 g. Test Example 1 Animal experiments were conducted on the effect of lactobionic acid on promoting mineral absorption. Animal experiments were performed using 6-week-old SD male rats in groups of 6 animals. As shown in Table 6, the experimental diet used was a mixture of 5% by weight of each saccharide. [Table 6] (Unit: g / 100g) ──────────────────────────────────── Group A Group B Group C──────────────────────────────────── casein 20.0 20.0 20.0 Corn starch 65.2 60.2 60.2 Cellulose 5.0 5.0 5.0 Corn oil 5.0 5.0 5.0 Vitamin mix 1.0 1.0 1.0 Methionine 3.5 3.5 3.5 DL-methionine 0.3 0.3 0.3 Lactose-5.0-Lactobionic acid--5.0 ─────────────────群 Group A: control group, Group B: lactose administration group, Group C: lactobionic acid administration group Table 7 shows the component values of each experimental meal. And Table 8 below. [Table 7] (Unit: g / 100g) Group A Group B Group C──────────────────────────────────── Carbohydrate 63.19 64.19 64.09 Protein 17.45 17.39 17.31 Fat 5.45 5.58 5.45 Moisture 10.82 9.81 10.10 Ash 3.09 3.03 3.05 A A Group: control group, Group B: lactose administration group, Group C: lactobionic acid administration group [Table 8] (Unit: mg / 100g)群 Group A Group B Group C───────────────────────── ─────────── Sodium 109 108 97 Potassium 350 350 350 Calcium 490 490 495 Magnesium 4 1 42 42 Iron 3.8 3.9 4.0 Zinc 3.6 3.7 3.6 Copper 0.55 0.55 0.56 Manganese 4.7 5.0 5.0 Phosphorus 600 610 610 ───────────────────────────群 Group A: control group, Group B: lactose-administered group, Group C: lactobionic acid-administered group.
One week after the administration of the experimental diet, feces and urine were collected, excreted calcium and magnesium were measured, and calculated by the following equation. Mineral absorption rate (%) = [(amount of ingested mineral−amount of excreted mineral) / (amount of ingested mineral) × 100 The results are shown in FIG. According to this, it was found that the lactobionic acid administration group promoted the absorption of minerals such as calcium and magnesium as compared with the lactose administration group known as a calcium absorbing substance. Test Example 2 21-day-old Wistar rats (body weight 45-
To 50 g), an iron-free diet (manufactured by Oriental Yeast Co., Ltd.) with an iron content of 0.25 mg / 100 g feed was given for 3 weeks to produce anemic rats having a blood hemoglobin value of 7 g / 100 ml or less. And 1
The group consisted of 5 animals, and the following test feed was orally administered at a rate of 1 ml / day for 6 weeks while continuing to receive the iron-free diet. Test group 1: ferrous iron-only diet Test group 2: 0.2 mg / ml of ferrous sulfate as iron Test group 3: 0.2 mg / ml of ferrous sulfate as iron + 200 mg / ml of lactobionic acid Test group 4: sulfate Six weeks after the administration of the test feed, 0.2 mg / ml lactose using iron as iron, blood was collected from the tail vein six weeks after administration of the test feed, and the hemoglobin value was measured using an automatic blood cell counter (manufactured by Toa Medical Electronics Co., Ltd.). Table 9 shows the results. 9 Hemoglobin value (mean ± standard) Deviation) ──────────────────────────────────── Test group 1 4.9 ± 0.3 (g / ml) test Group 2 10.5 ± 0.8 Test group 3 16.1 ± 1.0 Test group 4 11.6 ± 0.9 ───────────────────────────────── Thus, it was found that the lactobionic acid-administered group exhibited a better anemia treatment effect than the inorganic iron-ferrous sulfate alone-administered group and the lactose-administered group. Since the lactobionic acid of the present invention has an action of promoting the absorption of minerals, the medicine, food and drink and feed containing the lactobionic acid are useful for supplementing minerals.
【図面の簡単な説明】
【図1】は、試験例1のミネラル吸収促進効果について
の実験結果を示す。BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the experimental results of the mineral absorption promoting effect of Test Example 1.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI A61P 19/10 A61P 19/10 // C07H 15/04 C07H 15/04 F (56)参考文献 特開 平5−316997(JP,A) The American Jour nal of Clinical Nu trition,1982年,Vol.36, No.6,p.1162−1169 (58)調査した分野(Int.Cl.7,DB名) A61K 31/7032 A23L 1/29,1/30 A23K 1/16 303 C07H 3/00 - 3/10 C07H 7/00 - 7/06 C07H 15/04 REGISTRY(STN) CA(STN) MEDLINE(STN) EMBASE(STN) JICSTファイル(JOIS)──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification code FI A61P 19/10 A61P 19/10 // C07H 15/04 C07H 15/04 F (56) References JP-A-5-316997 (JP) , A) The American Journal of Clinical Nutrition, 1982, Vol. 36, No. 6, p. 1162-1169 (58) Field surveyed (Int.Cl. 7 , DB name) A61K 31/7032 A23L 1 / 29,1 / 30 A23K 1/16 303 C07H 3/00-3/10 C07H 7/00-7 / 06 C07H 15/04 REGISTRY (STN) CA (STN) MEDLINE (STN) EMBASE (STN) JICST file (JOIS)
Claims (1)
ル吸収促進剤。(57) [Claims] (1) A mineral absorption promoter comprising lactobionic acid as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08557794A JP3501237B2 (en) | 1994-03-31 | 1994-03-31 | Mineral absorption enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08557794A JP3501237B2 (en) | 1994-03-31 | 1994-03-31 | Mineral absorption enhancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07277991A JPH07277991A (en) | 1995-10-24 |
| JP3501237B2 true JP3501237B2 (en) | 2004-03-02 |
Family
ID=13862674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP08557794A Expired - Lifetime JP3501237B2 (en) | 1994-03-31 | 1994-03-31 | Mineral absorption enhancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3501237B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007116972A (en) * | 2005-10-27 | 2007-05-17 | Unitika Ltd | Bone fracture preventive agent, and slipped tendon preventive agent |
| JP2008001608A (en) * | 2006-06-20 | 2008-01-10 | Unitika Ltd | Ecole production promoting composition |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9806444D0 (en) * | 1998-03-25 | 1998-05-27 | Mars Uk Ltd | Food |
| EP1594364A1 (en) * | 2003-02-14 | 2005-11-16 | Mars Uk Limited | Skin composition |
| US20040170724A1 (en) * | 2003-02-28 | 2004-09-02 | Kraft Foods Holdings, Inc. | Mineral complexes of lactobionic acid and method of using for mineral fortification of food products |
| NO320989B1 (en) * | 2003-12-05 | 2006-02-20 | Pigeon Vitality As | Feed additive containing a carboxylic acid and / or its salt as a basic component of the additive. |
| US20070190115A1 (en) * | 2004-02-06 | 2007-08-16 | Takashi Kimura | Feed additive for laying hen and feed containing the same |
| US7267832B2 (en) | 2004-02-18 | 2007-09-11 | Kraft Foods Holdings, Inc. | Amorphous water-soluble calcium citrate salts and method of making and using same |
| JP2008303208A (en) * | 2007-05-09 | 2008-12-18 | Unitika Ltd | Mineral absorption enhancer |
| EP2204098A1 (en) * | 2008-12-19 | 2010-07-07 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Flavour enhancer |
| DE102011008017A1 (en) * | 2011-01-06 | 2012-07-12 | Johannes F. Coy | soft drink |
| CN103005165B (en) * | 2013-01-08 | 2014-03-19 | 长沙兴嘉动物营养科技有限公司 | Preparation method of lactobionic acid microelement complex and application of complex as animal feed additive |
| WO2015190573A1 (en) * | 2014-06-11 | 2015-12-17 | 株式会社Biomaterial in Tokyo | Composition for preventing and/or improving iron-deficiency anemia, and composition for preventing and/or improving indefinite complaints associated with iron-deficiency anemia |
-
1994
- 1994-03-31 JP JP08557794A patent/JP3501237B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| The American Journal of Clinical Nutrition,1982年,Vol.36, No.6,p.1162−1169 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007116972A (en) * | 2005-10-27 | 2007-05-17 | Unitika Ltd | Bone fracture preventive agent, and slipped tendon preventive agent |
| JP2008001608A (en) * | 2006-06-20 | 2008-01-10 | Unitika Ltd | Ecole production promoting composition |
| US8822432B2 (en) | 2006-06-20 | 2014-09-02 | Unitika Ltd. | Equol production accelerating composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07277991A (en) | 1995-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3501237B2 (en) | Mineral absorption enhancer | |
| JP2983503B2 (en) | Iron-calcium mineral supplement with high bioavailability | |
| CA2494773C (en) | Calcium absorption enhancer | |
| US20210260015A1 (en) | Composition for inhibiting fat accumulation | |
| JPH07252156A (en) | Medicine for prevention and therapy of osteoporosis | |
| JPH0124768B2 (en) | ||
| GB2028341A (en) | Hypo- beta -lipoproteinaemic dietetic composition | |
| JP5281895B2 (en) | Calcium absorption promoter | |
| JP3279694B2 (en) | Mineral absorption enhancer containing lactulose oligosaccharide as active ingredient | |
| WO2015198480A1 (en) | Solid composition | |
| JPWO2004084919A1 (en) | Food for pathological improvement that reduces the concentration of low molecular weight nitrogen-containing compounds in the blood | |
| JP5122766B2 (en) | Ecole production promoting composition | |
| JP6608193B2 (en) | Solid composition | |
| JP6525586B2 (en) | Solid composition | |
| JP3248170B2 (en) | Food containing chondroitin sulfate protein complex | |
| JPH08283162A (en) | Mineral absorption promoter | |
| JP3279695B2 (en) | Mineral absorption enhancer containing branched galactooligosaccharide as active ingredient | |
| JP2002281941A (en) | Food preparation with high calcium content | |
| JP2012188426A (en) | Lipid metabolism-improving composition | |
| US20060141122A1 (en) | Use of germ flour of certain fruits for the manufacture of food products useful for the treatment of phytate deficiency states | |
| JP2007236201A (en) | Mineral strengthening composition | |
| JPS6368045A (en) | Protein composition for food | |
| WO2006038613A1 (en) | Oral composition containing difructose anhydride | |
| JP4070844B2 (en) | Magnesium-containing oral composition | |
| JP3708500B2 (en) | High protein baked food and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20031126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031126 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081212 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081212 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091212 Year of fee payment: 6 |
|
| S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101212 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101212 Year of fee payment: 7 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101212 Year of fee payment: 7 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 8 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 8 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 8 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131212 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term |